Mr Paul Scott Elieson, PT in Beaver, UT - Physical Therapist

Mr Paul Scott Elieson, PT is a Physical Therapist based in Beaver, Utah. Mr Paul Scott Elieson is licensed to practice in Utah (license number 120210-2401) and his current practice location is 85 N. 400 E., Beaver, Utah. He can be reached at his office (for appointments etc.) via phone at (435) 438-1214.

NPI number for Mr Paul Scott Elieson is 1558357251 and his current mailing address is Po Box 2244, Beaver, Utah. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1558357251.

Contact Information

	Mr Paul Scott Elieson, PT
	85 N. 400 E., Beaver, UT 84713-2244
	(435) 438-1214
	(435) 438-5482

Healthcare Provider's Profile

Full Name	Mr Paul Scott Elieson
Gender	Male
Speciality	Physical Therapist
Location	85 N. 400 E., Beaver, Utah
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1558357251
Provider Enumeration Date: 09/27/2005
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mr Paul Scott Elieson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1558357251	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	120210-2401 (Utah)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Paul Scott Elieson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Paul Scott Elieson, PT Po Box 2244, Beaver, UT 84713-2244 Ph: (435) 438-1214	Mr Paul Scott Elieson, PT 85 N. 400 E., Beaver, UT 84713-2244 Ph: (435) 438-1214

News Archive

New compound could treat certain types of genetic disorders in muscles

Scientists at UCLA have identified a new compound that could treat certain types of genetic disorders in muscles. It is a big first step in what they hope will lead to human clinical trials for Duchenne muscular dystrophy.

FDA advisory committee vote 16-0 for first even gene therapy for rare blindness

A panel of advisors to the United States Food and Drug Administration (FDA) has voted unanimously in favor of an experimental gene therapy to treat patients with a rare kind of hereditary blindness.

Epigenomics receives FDA approval for Epi proColon®

Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company's lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer screening test.

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Aradigm Corporation announced today that it received the $4 million milestone payment from Zogenix, Inc. ("Zogenix") based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free delivery system. The Company will receive quarterly royalty payments on all SUMAVEL DosePro sales. In 2006, the Company sold all assets related to the Intraject* needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.

Salt could be 'nature's antidepressant' according to new research

Most people consume far too much salt, and a University of Iowa researcher has discovered one potential reason we crave it: it might put us in a better mood.

Mr Paul Scott Elieson, PT - Physical Therapist in Beaver, UT